Business Context and Reporting Period
Company: ORIC Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 13, 2025
Reporting Period: Fiscal quarter ended September 30, 2025
Context: The Company issued a press release announcing its financial results for the quarter ended September 30, 2025. The full details of these results are contained in Exhibit 99.1 (Press Release), which is incorporated by reference.
Key Financial Metrics
The provided Form 8-K text serves as a cover document referencing the press release for financial data. It does not contain specific numerical values for the following metrics:
- Revenue: Not provided in the filing text.
- Profit/Loss: Not provided in the filing text.
- Cash Flow: Not provided in the filing text.
- Margins: Not provided in the filing text.
- Debt and Liquidity: Not provided in the filing text.
Material Changes
The filing text does not provide specific data to compare current period performance against the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year or quarter-over-quarter comparisons.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing text does not include specific guidance, forward-looking statements, or management commentary beyond the announcement of the results.
Risks and Contingencies: No specific risks or contingencies are detailed in the text of this Form 8-K.
Unusual Items: No unusual items are described in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 13, 2025) for actual revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as disclosed in the press release, given the lack of data in the 8-K summary.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm if the Company has updated its full-year financial guidance in the referenced press release.